Cibinetide 10mg ARA 290 Peptide 99% Purity Cas 1208243-50-8 CAS NO.1208243-50-8

Wuhan Senwayer century chemical Co..Ltd located in the predominant Wuhan City where is a traffic hinge of China, specialize in producing and developing pharmaceutical & its intermediates, Pesticide Intermediate, food additive, Plant extracts,and in distributing the products of our own company and affiliated enterprises.

We have set up R&D center, quality inspection center and manufacturing site in Wuhan, Jiangsu and other places.

Our company has professional staff who deal with chemical R&D and scientific management, and holds several sets of analyzing instruments with high efficiency and high sensitivity, such as HPLC, GC and Spectrophotometer. Meanwhile, we possess of complete Q.A. and Q.C. system, supply chemical products with good quality and custom-tailored products according to our clients' requirement.

We have professional sales team, focus on quality and service, and we have achieved excellent performance over the years. Our company is committed to the development of international market , our products are mainly exported to many countries and regions, such as Europe, America, South-east Asia, the Middle East and Africa etc. With our constant efforts and good service, We sincerely hope to establish long-term cooperation and common development with our customers.

Introduction

ARA-290 is a peptide that is derived from erythropoietin (EPO). EPO has been utilized for decades because of its ability to stimulate red blood cell production within bone marrow. It can also alter a patient’s blood pressure, promote cell survival, and create a neuroprotective effect.

While ARA-290 does not stimulate red blood cell production, it does offer pain-relieving and neuroprotective effects. It also has the potential to stimulate wound repair in patients with chronic diabetes, but this property is still being researched.

Benefits of ARA-290

The full scope of ARA-290s benefits is still being researched. However, it has the potential to decrease the user’s inflammatory pathways through a process known as paracrine signaling. It has also been linked to reduced HbA1c and improved cholesterol numbers. Studies that have produced these results are still in the trial stages.

Perhaps the most appealing possibility for ARA-290 is that it may have the ability to reduce neuropathic symptoms and stimulate natural wound repair processes.

This peptide serves as an exciting treatment option for patients that are dealing with chronic neuropathic pain and diabetes-related ailments. It can also be safely paired with other peptides like BPC-157, which has healing properties.